Multiplex genetic cancer testing identifies pathogenic mutations in TP53 and CDH1 in a patient with bilateral breast and endometrial adenocarcinoma

BMC Medical Genetics

Volumn 14, Issue 1, 2013, Pages

  Heitzer, Ellen ^a   Lax, Sigurd ^b   Lafer, Ingrid ^a   Müller, Stephanie M ^a   Pristauz, Gunda ^a   Ulz, Peter ^a   Jahn, Stephan ^a   Högenauer, Christoph ^a   Petru, Edgar ^a   Speicher, Michael R ^a   Geigl, Jochen B ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b General Hospital Graz West   (Austria)

Author keywords

Cancer susceptibility; CDH1; Multiplex genetic testing; Next generation sequencing; NGS; TP53

Indexed keywords

ADENOCARCINOMA; BREAST NEOPLASMS; CADHERINS; ENDOMETRIAL NEOPLASMS; FEMALE; GENETIC TESTING; HUMANS; MALE; MIDDLE AGED; MUTATION; PEDIGREE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84890969390     PISSN: None     EISSN: 14712350     Source Type: Journal    
DOI: 10.1186/1471-2350-14-129     Document Type: Article

References (20)

1. Weitzel JN, Blazer KR, Macdonald DJ, Culver JO, Offit K. Genetics, genomics, and cancer risk assessment: state of the art and future directions in the Era of personalized medicine. CA Cancer J Clin 2011, 61:327-359.
2. Speicher MR, Geigl JB, Tomlinson IP. Effect of genome-wide association studies, direct-to-consumer genetic testing, and high-speed sequencing technologies on predictive genetic counselling for cancer risk. Lancet Oncol 2010, 11:890-898. 10.1016/S1470-2045(09)70359-6, 20537948.
3. Domchek SM, Bradbury A, Garber JE, Offit K, Robson ME. Multiplex genetic testing for cancer susceptibility: out on the high wire without a net?. J Clin Oncol 2013, 31:1267-1270. 10.1200/JCO.2012.46.9403, 23460708.
4. Shannon KM, Chittenden A. Genetic testing by cancer site: breast. Cancer J 2012, 18:310-319. 10.1097/PPO.0b013e318260946f, 22846731.
5. Mai PL, Malkin D, Garber JE, Schiffman JD, Weitzel JN, Strong LC, Wyss O, Locke L, Means V, Achatz MI, Hainaut P, Frebourg T, Evans DG, Bleiker E, Patenaude A, Schneider K, Wilfond B, Peters JA, Hwang PM, Ford J, Tabori U, Ognjanovic S, Dennis PA, Wentzensen IM, Greene MH, Fraumeni JF, Savage SA. Li-Fraumeni syndrome: report of a clinical research workshop and creation of a research consortium. Cancer Gene 2012, 205:479-487.
6. Olivier M, Goldgar DE, Sodha N, Ohgaki H, Kleihues P, Hainaut P, Eeles RA. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res 2003, 63:6643-6650.
7. Chompret A, Abel A, Stoppa-Lyonnet D, Brugieres L, Pages S, Feunteun J, Bonaiti-Pellie C. Sensitivity and predictive value of criteria for p53 germline mutation screening. J Med Genet 2001, 38:43-47. 10.1136/jmg.38.1.43, 1734716, 11332399.
8. Tinat J, Bougeard G, Baert-Desurmont S, Vasseur S, Martin C, Bouvignies E, Caron O, Bressac-de Paillerets B, Berthet P, Dugast C, Bonaiti-Pellie C, Stoppa-Lyonnet D, Frebourg T. 2009 version of the Chompret criteria for Li Fraumeni syndrome. J Clin Oncol 2009, 27:e108-109. author reply e110, 10.1200/JCO.2009.22.7967, 19652052.
9. Oliveira C, Pinheiro H, Figueiredo J, Seruca R, Carneiro F. E-cadherin alterations in hereditary disorders with emphasis on hereditary diffuse gastric cancer. Prog Mol Biol Transl Sci 2013, 116:337-359.
10. Fitzgerald RC, Hardwick R, Huntsman D, Carneiro F, Guilford P, Blair V, Chung DC, Norton J, Ragunath K, Van Krieken JH, Dwerryhouse S, Caldas C. International gastric cancer linkage C: hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet 2010, 47:436-444. 10.1136/jmg.2009.074237, 2991043, 20591882.
11. Walsh T, Casadei S, Coats KH, Swisher E, Stray SM, Higgins J, Roach KC, Mandell J, Lee MK, Ciernikova S, Foretova L, Soucek P, King MC. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 2006, 295:1379-1388. 10.1001/jama.295.12.1379, 16551709.
12. Brooks-Wilson AR, Kaurah P, Suriano G, Leach S, Senz J, Grehan N, Butterfield YS, Jeyes J, Schinas J, Bacani J, Kelsey M, Ferreira P, MacGillivray B, MacLeod P, Micek M, Ford J, Foulkes W, Australie K, Greenberg C, LaPointe M, Gilpin C, Nikkel S, Gilchrist D, Hughes R, Jackson CE, Monaghan KG, Oliveira MJ, Seruca R, Gallinger S, Caldas C, et al. Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria. J Med Genet 2004, 41:508-517. 10.1136/jmg.2004.018275, 1735838, 15235021.
13. Mateus AR, Simoes-Correia J, Figueiredo J, Heindl S, Alves CC, Suriano G, Luber B, Seruca R. E-cadherin mutations and cell motility: a genotype-phenotype correlation. Exp Cell Res 2009, 315:1393-1402. 10.1016/j.yexcr.2009.02.020, 19268661.
14. Bougeard G, Limacher JM, Martin C, Charbonnier F, Killian A, Delattre O, Longy M, Jonveaux P, Fricker JP, Stoppa-Lyonnet D, Flaman JM, Frebourg T. Detection of 11 germline inactivating TP53 mutations and absence of TP63 and HCHK2 mutations in 17 French families with Li-Fraumeni or Li-Fraumeni-like syndrome. J Med Genet 2001, 38:253-257. 10.1136/jmg.38.4.253, 1734839, 11370630.
15. Verselis SJ, Rheinwald JG, Fraumeni JF, Li FP. Novel p53 splice site mutations in three families with Li-Fraumeni syndrome. Oncogene 2000, 19:4230-4235. 10.1038/sj.onc.1203758, 10980596.
16. Masciari S, Dewanwala A, Stoffel EM, Lauwers GY, Zheng H, Achatz MI, Riegert-Johnson D, Foretova L, Silva EM, Digianni L, Verselis SJ, Schneider K, Li FP, Fraumeni J, Garber JE, Syngal S. Gastric cancer in individuals with Li-Fraumeni syndrome. Genet Med 2011, 13:651-657. 10.1097/GIM.0b013e31821628b6, 3595598, 21552135.
17. Chompret A, Brugieres L, Ronsin M, Gardes M, Dessarps-Freichey F, Abel A, Hua D, Ligot L, Dondon MG, Bressac-de Paillerets B, Frebourg T, Lemerle J, Bonaiti-Pellie C, Feunteun J. P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer 2000, 82:1932-1937. 2363254, 10864200.
18. Villani A, Tabori U, Schiffman J, Shlien A, Beyene J, Druker H, Novokmet A, Finlay J, Malkin D. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. Lancet Oncol 2011, 12:559-567. 10.1016/S1470-2045(11)70119-X, 21601526.
19. Kaurah P, MacMillan A, Boyd N, Senz J, De Luca A, Chun N, Suriano G, Zaor S, Van Manen L, Gilpin C, Nikkel S, Connolly-Wilson M, Weissman S, Rubinstein WS, Sebold C, Greenstein R, Stroop J, Yim D, Panzini B, McKinnon W, Greenblatt M, Wirtzfeld D, Fontaine D, Coit D, Yoon S, Chung D, Lauwers G, Pizzuti A, Vaccaro C, Redal MA, et al. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA 2007, 297:2360-2372. 10.1001/jama.297.21.2360, 17545690.
20. Couzin-Frankel J. Genome sequencing. Return of unexpected DNA results urged. Science 2013, 339:1507-1508. 10.1126/science.339.6127.1507, 23539571.